AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25268286
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Strength and Flexibility (ST + FLEX)
Trial: 25268286
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Flexibility and Strength (FLEX + ST)
Trial: 21352389
Drug: Medication with
RxNorm normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with citalopram
Trial: 21352389
Drug: Medication with
RxNorm normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with reboxetine
Trial: 21352389
Drug: Exclusive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exclusive treatment with psychotherapy
Trial: 18045825
Drug: ISN/RPS class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISN/RPS class IV‐S and IV‐G
Trial: 16925808
Drug: Aspirin (81-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81-100 mg/day)
Trial: 16925808
Drug: Cilostazol (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100-200 mg/day)
Trial: 10837300
Drug: Beta-carotene (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (42 mg all-trans-beta-carotene)
Trial: 2871184
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (16 sessions of progressive relaxation, desensitization, and EMG biofeedback)
Trial: 22940056
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of influenza vaccine
Trial: 22940056
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of influenza vaccine
Trial: 21575100
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 mcg·kg(‐1) (F1 group)
Trial: 21575100
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 mcg·kg(‐1) (F2 group)
Trial: 21575100
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg·kg(‐1) (K group)
Trial: 21575100
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 mcg·kg(‐1) plus Ketamine 0.5 mg·kg(‐1) (FK group)
Trial: 18465334
Drug: Classical CMF
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical CMF (oral cyclophosphamide days 1-14, intravenous methotrexate and fluorouracil on days 1 and 8, repeated every 28 days)
Trial: 18465334
Drug: Four-weekly intravenous
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-weekly intravenous CMF
Trial: 18465334
Drug: Three-weekly intravenous
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-weekly intravenous CMF
Trial: 17290563
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (80 mg elementary iron)
Trial: 12847992
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Vitamin C
Trial: 12847992
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Omega-3 fatty acids
Trial: 12847992
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Vitamin C + 1 g Omega-3 fatty acids
Trial: 11429120
Drug: rIFN‐gamma 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma 0.05 mg/m(2) subcutaneously three times weekly for 48 weeks
Trial: 7978409
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (EF), 10 micrograms/mL in saline
Trial: 2929911
Drug: Morphine 0.5
RxNorm normalized name: morphine 0.5 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.5 mg
Trial: 19925723
Drug: Larval therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larval therapy (loose and bagged pooled)
Trial: 19925723
Drug: Larval therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larval therapy
Trial: 17174502
Drug: Barium sulphate
RxNorm normalized name: Barium sulphate
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barium sulphate + iodinated hyperosmolar contrast agent (Gastrografin)
Trial: 17174502
Drug: Barium sulphate
RxNorm normalized name: Barium sulphate
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barium sulphate + both iodinated hyperosmolar contrast agent and effervescent granules
Trial: 11860218
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 800 microg/daily b.i.d. (n = 66)
Trial: 11860218
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 1000 microg/daily b.i.d. (n = 61)
Trial: 29211620
Drug: quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quadrivalent HPV vaccine (qHPV)
Trial: 30261146
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (9vHPV and qHPV)
Trial: 28923786
Drug: SYNERGY half-dose
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNERGY half-dose
Trial: 27159854
Drug: Transnasal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal injection of 2 mL of 1% lidocaine + epinephrine 1:100,000 + GPC injection
Trial: 27159854
Drug: Transnasal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal injection of 2 mL of 1% lidocaine + epinephrine 1:100,000 (monotherapy)
Trial: 23928675
Drug: Topical nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical nepafenac
Trial: 20733445
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate
Trial: 18215612
Drug: ximelagatran with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ximelagatran with aspirin
Trial: 18215612
Drug: aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin alone (placebo)
Trial: 10227004
Drug: 50 micrograms/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms/day 17 beta‐estradiol for 14 weeks, combined with oral medroxyprogesterone acetate 10 mg/day during the last 2 weeks
Trial: 10227004
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14 weeks, combined with oral medroxyprogesterone acetate 10 mg/day during the last 2 weeks
Trial: 8929263
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (identical procedure but radio-frequency current not turned on)
Trial: 1831505
Drug: Tetracycline (TC)
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline (TC) fiber therapy
Trial: 1831505
Drug: Control fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control fiber (fibers without drug)
Trial: 6181041
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with intradermal administration of methanol extraction residue of BCG (MER) and split course megavoltage radiotherapy (5,000 rad over 7 weeks)
Trial: 30089135
Drug: Galantamine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (both doses)
Trial: 20170591
Drug: Natural grape
RxNorm normalized name: Walgreens Finest Natural Grapeseed 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural grape juice (18 ml/kg/day) for 1 month
Trial: 20170591
Drug: Natural pomegranate
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural pomegranate juice (240 ml/day) for 1 month
Trial: 10406247
Drug: Topical pharyngeal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pharyngeal anesthesia with 2% tetracaine/14% benzocaine spray
Trial: 2209278
Drug: Gentamicin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (3 mg/kg/day for five days) with metronidazole (1.5 gm)
Trial: 31259738
Drug: Tenofovir (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir (1% gel)
Trial: 31259738
Drug: Dapivirine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine (25 mg in vaginal ring)
Trial: 28937531
Drug: Intranasal DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DEX (2 μg/kg)
Trial: 12901592
Drug: Twinrix vaccine
RxNorm normalized name: TWINRIX vaccine 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twinrix vaccine (0‐, 1‐, 6‐month vaccination schedule)
Trial: 11051122
Drug: LEV 1500
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 1500 mg twice daily (monotherapy)
Trial: 11051122
Drug: LEV 1500
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 1500 mg twice daily (add-on phase)
Trial: 11051122
Drug: LEV 3000
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 3000 mg/d (add-on phase)
Trial: 23913917
Drug: Self-administered, computer-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered, computer-assisted self-management
Trial: 23913917
Drug: Self-administered program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered program with enhanced social support
Trial: 22443839
Drug: Short family
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short family intervention with five weekly home‐based intervention sessions
Trial: 8907403
Drug: Peer-led drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-led drug prevention program
Trial: 8907403
Drug: Adult-led drug
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult-led drug prevention program
Trial: 573558
Drug: Bupivacaine mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine mixed with chloroprocaine (0.5 mg bupivacaine and 3 mg chloroprocaine)
Trial: 573558
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (0.5 mg)
Trial: 573558
Drug: Chloroprocaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine alone (3 mg)
Trial: 9808683
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg three times daily
Trial: 7447770
Drug: Once-a-day 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-a-day 0.25% timolol ophthalmic solution
Trial: 7447770
Drug: Twice-a-day 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day 0.25% timolol ophthalmic solution
Trial: 27956003
Drug: Anacetrapib 25
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib 25 mg
Trial: 23663521
Drug: Person-centred proactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Person-centred proactive telephone support (daily for up to 14 days after hospital discharge)
Trial: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 15 mg
Trial: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 30 mg
Trial: 16324916
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 45 mg
Trial: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 15 mg plus Sulfonylurea (SU)
Trial: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 30 mg plus Sulfonylurea (SU)
Trial: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 30 mg plus Metformin (MET)
Trial: 11598535
Drug: LV5FU2 low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LV5FU2 low dose
Trial: 11598535
Drug: LV5FU2 high
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5FU2 high dose
Trial: 11598535
Drug: 5FU weekly
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5FU weekly
Trial: 11598535
Drug: Weekly 5FU
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly 5FU
Trial: 7593726
Drug: Moclobemide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (400 mg daily)
Trial: 3719424
Drug: Bupivacaine (0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.25% solution, 25 mg first dose, 10 ml, reinjections every hour for 10 mg)
Trial: 3719424
Drug: 2-Chloroprocaine (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-Chloroprocaine (2% solution, 200 mg first dose, 10 ml, reinjections every 30 min for 80 mg)
Trial: 31218738
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention to improve OAC prescription
Trial: 31218738
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of OACs at admission
Trial: 27460100
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days)
Trial: 27460100
Drug: 14-day modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day)
Trial: 27460100
Drug: Modified bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified bismuth quadruple therapy
Trial: 24392946
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly 56.5 μg teriparatide
Trial: 22569710
Drug: OCP +
RxNorm normalized name: Oral Contraceptive Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP + GnRH agonist
Trial: 22569710
Drug: OCP +
RxNorm normalized name: Oral Contraceptive Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP + GnRH antagonist
Trial: 20332770
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg once daily for 28 days
Trial: 20332770
Drug: placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily for 28 days
Trial: 17383926
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin (BoNT) injections into the submandibular glands
Trial: 17383926
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin (BoNT) injections into the parotid glands
Trial: 17383926
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between submandibular and parotid injections
Trial: 15709833
Drug: Other forms
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other forms of treatment (pharmacotherapy either alone or in combination with family therapy)
Trial: 10422923
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled morphine
Trial: 7766565
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g raw potato starch (550 g RS/kg)
Trial: 7766565
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g pregelatinized potato starch (0 g RS/kg)
Trial: 7766565
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g pregelatinized potato starch plus 20 g lactulose (670 g indigestible disaccharide/kg)
Trial: 2288551
Drug: VT =
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VT = 12 ml/kg (group 1)
Trial: 2288551
Drug: VT =
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VT = 6 ml/kg (group 2)
Trial: 6969109
Drug: Cephalothin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin prophylaxis administered intraoperatively
Trial: 6969109
Drug: Cephalothin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin prophylaxis administered both intraoperatively and postoperatively
Trial: 31417058
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dose of ferrous sulphate (65 mg elemental iron)
Trial: 31417058
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dose of ferrous sulphate (130 mg elemental iron)
Trial: 28524699
Drug: Nifedipine CR
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine CR (80 mg)/candesartan (8 mg)
Trial: 28524699
Drug: Amlodipine (10 mg)/candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg)/candesartan (8 mg)
Trial: 20925019
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg for 6 days)
Trial: 19951216
Drug: Purified red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified red clover (Trifolium pratense) isoflavone (86 mg/day) tablets
Trial: 17294808
Drug: Trimetazidine tablets
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine tablets (two brands)
Trial: 11703344
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) - 2 mg 17‐beta‐oestradiol and 1 mg norethisterone acetate
Trial: 26971745
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shockwave therapy (rESWT)
Trial: 25205381
Drug: Eyes Open
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyes Open (EO) at 0.25 Hz (L)
Trial: 25205381
Drug: Eyes Closed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyes Closed (EC) at 0.25 Hz (L)
Trial: 18930568
Drug: Cilazapril alone
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril alone (ACE-inhibitor group; n = 30)
Trial: 18930568
Drug: Steroid plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid plus cilazapril (combination group; n = 33)
Trial: 18930568
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (hazard ratio, 0.1; 95% CI, 0.014 to 0.946)
Trial: 11235580
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus chemotherapy
Trial: 11235580
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus brachytherapy and chemotherapy
Trial: 6389147
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg metoclopramide
Trial: 6389147
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg metoclopramide
Trial: 6389147
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg metoclopramide
Trial: 28632555
Drug: Manual Treatment
RxNorm normalized name: Pari Manual Interrupter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Treatment (MT)
Trial: 28632555
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (LBP)
Trial: 24954745
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg biweekly) and Docetaxel (20 mg/m² weekly) with Radiation Therapy (RT)